Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis.

Yu Ri Im, Rukmini Jagdish, Damien Leith, Jin Un Kim, Kyoko Yoshida, Amir Majid, Yueqi Ge, Gibril Ndow, Yusuke Shimakawa, Maud Lemoine
{"title":"Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis.","authors":"Yu Ri Im,&nbsp;Rukmini Jagdish,&nbsp;Damien Leith,&nbsp;Jin Un Kim,&nbsp;Kyoko Yoshida,&nbsp;Amir Majid,&nbsp;Yueqi Ge,&nbsp;Gibril Ndow,&nbsp;Yusuke Shimakawa,&nbsp;Maud Lemoine","doi":"10.1016/S2468-1253(22)00201-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite growing concerns about transmissibility and clinical impact, occult hepatitis B virus (HBV) infection has received little attention in the hepatitis elimination agenda. We aimed to estimate the prevalence of occult HBV infection at a global and regional scale and in specific populations.</p><p><strong>Methods: </strong>For this systematic review and meta-analysis, we searched the MEDLINE, Embase, Global Health, and Web of Science databases for articles published in any language between Jan 1, 2010, and Aug 14, 2019. We included original articles and conference abstracts of any study design that reported the proportion of HBsAg-negative adults (aged ≥18 years) who are positive for HBV DNA (ie, people with occult HBV infection). The prevalence of occult HBV infection was pooled, using the DerSimonian-Laird random-effects model, in the general population and specific groups defined by the type of study participants (blood donors; other low-risk populations; high-risk populations; and people with advanced chronic liver disease), and stratified by HBV endemicity in each country. We also assessed the performance of anti-HBc as an alternative biomarker to detect occult HBV infection. The study was registered with PROSPERO, CRD42019115490.</p><p><strong>Findings: </strong>305 of 3962 articles were eligible, allowing a meta-analysis of 140 521 993 individuals tested for HBV DNA. Overall, only two studies evaluated occult HBV infection in the general population, precluding unbiased global and regional estimates of occult HBV infection prevalence. In blood donors, occult HBV infection prevalence mirrored HBV endemicity: 0·06% (95% CI 0·00-0·26) in low-endemicity countries, 0·12% (0·04-0·23) in intermediate-endemicity countries, and 0·98% (0·44-1·72), in high-endemicity countries (p=0·0012). In high-risk groups, occult HBV infection prevalence was substantial, irrespective of endemicity: 5·5% (95% CI 2·9-8·7) in low-endemicity countries, 5·2% (2·5-8·6) in intermediate-endemicity countries, and 12·0% (3·4-24·7) in high-endemicity countries. The pooled sensitivity of anti-HBc to identify occult HBV infection was 77% (95% CI 62-88) and its specificity was 76% (68-83).</p><p><strong>Interpretation: </strong>A substantial proportion of people carry occult HBV infection, especially among high-risk groups across the globe and people living in highly endemic countries. Occult HBV infection should be part of the global viral hepatitis elimination strategy.</p><p><strong>Funding: </strong>None.</p>","PeriodicalId":114609,"journal":{"name":"The lancet. Gastroenterology & hepatology","volume":" ","pages":"932-942"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630161/pdf/","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The lancet. Gastroenterology & hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2468-1253(22)00201-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

Background: Despite growing concerns about transmissibility and clinical impact, occult hepatitis B virus (HBV) infection has received little attention in the hepatitis elimination agenda. We aimed to estimate the prevalence of occult HBV infection at a global and regional scale and in specific populations.

Methods: For this systematic review and meta-analysis, we searched the MEDLINE, Embase, Global Health, and Web of Science databases for articles published in any language between Jan 1, 2010, and Aug 14, 2019. We included original articles and conference abstracts of any study design that reported the proportion of HBsAg-negative adults (aged ≥18 years) who are positive for HBV DNA (ie, people with occult HBV infection). The prevalence of occult HBV infection was pooled, using the DerSimonian-Laird random-effects model, in the general population and specific groups defined by the type of study participants (blood donors; other low-risk populations; high-risk populations; and people with advanced chronic liver disease), and stratified by HBV endemicity in each country. We also assessed the performance of anti-HBc as an alternative biomarker to detect occult HBV infection. The study was registered with PROSPERO, CRD42019115490.

Findings: 305 of 3962 articles were eligible, allowing a meta-analysis of 140 521 993 individuals tested for HBV DNA. Overall, only two studies evaluated occult HBV infection in the general population, precluding unbiased global and regional estimates of occult HBV infection prevalence. In blood donors, occult HBV infection prevalence mirrored HBV endemicity: 0·06% (95% CI 0·00-0·26) in low-endemicity countries, 0·12% (0·04-0·23) in intermediate-endemicity countries, and 0·98% (0·44-1·72), in high-endemicity countries (p=0·0012). In high-risk groups, occult HBV infection prevalence was substantial, irrespective of endemicity: 5·5% (95% CI 2·9-8·7) in low-endemicity countries, 5·2% (2·5-8·6) in intermediate-endemicity countries, and 12·0% (3·4-24·7) in high-endemicity countries. The pooled sensitivity of anti-HBc to identify occult HBV infection was 77% (95% CI 62-88) and its specificity was 76% (68-83).

Interpretation: A substantial proportion of people carry occult HBV infection, especially among high-risk groups across the globe and people living in highly endemic countries. Occult HBV infection should be part of the global viral hepatitis elimination strategy.

Funding: None.

Abstract Image

Abstract Image

Abstract Image

成人隐匿性乙型肝炎病毒感染的患病率:一项系统回顾和荟萃分析。
背景:尽管人们越来越关注隐性乙型肝炎病毒(HBV)的传播性和临床影响,但在消除肝炎的议程中,隐性乙型肝炎病毒(HBV)感染很少受到关注。我们的目的是在全球和区域范围内以及在特定人群中估计隐性HBV感染的患病率。方法:在这项系统评价和荟萃分析中,我们检索了MEDLINE、Embase、Global Health和Web of Science数据库,检索了2010年1月1日至2019年8月14日期间以任何语言发表的文章。我们纳入了所有报道HBV DNA阳性的hbsag阴性成人(年龄≥18岁)(即隐匿性HBV感染人群)比例的研究设计的原创文章和会议摘要。使用DerSimonian-Laird随机效应模型,汇总了普通人群和根据研究参与者类型(献血者;其他低风险人群;高危人群;以及晚期慢性肝病患者),并根据每个国家的HBV流行情况进行分层。我们还评估了抗hbc作为检测隐匿性HBV感染的替代生物标志物的性能。该研究已在PROSPERO注册,编号为CRD42019115490。结果:3962篇文章中有305篇符合条件,允许对140 521 993名HBV DNA检测个体进行荟萃分析。总的来说,只有两项研究评估了普通人群中的隐性HBV感染,排除了对隐性HBV感染流行率的无偏倚全球和区域估计。在献血者中,隐性HBV感染患病率反映了HBV的地方性:在低流行国家为0.06% (95% CI为0.0000 - 0.26),在中流行国家为0.12%(0.004 - 0.23),在高流行国家为0.98% (0.44 - 0.72)(p= 0.0012)。在高危人群中,隐性HBV感染流行率很高,与地方性无关:低流行国家为5.5% (95% CI 2.9 - 8.7),中流行国家为5.5% (95% CI 2.5 - 8.6),高流行国家为12.0%(3.4 - 24.7)。抗- hbc鉴别隐匿性HBV感染的总敏感性为77% (95% CI 62-88),特异性为76%(68-83)。解释:相当大比例的人携带隐性HBV感染,特别是在全球的高危人群和高流行国家的人群中。隐匿性HBV感染应成为全球消除病毒性肝炎战略的一部分。资金:没有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信